Market Scenario
Radiopharmaceuticals are those radioisotopes that are primarily used for diagnosis and therapeutic purposes. Radioisotopes can be used for diagnosis and treatment of various chronic diseases. Radioisotopes play a very crucial part in the medical diagnostic procedures. In combination with imaging devices which record the gamma rays emitted from inside, healthcare professionals can study the dynamic processes taking place in various parts of the body.
The global radiopharmaceutical market is expected to grow at a CAGR of 8.7% during the forecast period 2017–2023. The market’s growth is mainly attributed to the increasing prevalence of chronic diseases, which is creating a greater need for early diagnosis and treatment modules. Moreover, rising expenditure in oncology and growing emphasis on cancer management has also accelerated the market growth. However, the high cost of device and low feasibility of treatment is undermining the potentials of the market to some extent. The risks associated with the use of radiopharmaceuticals also acts as a growth barrier for the market.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/1650
Segmentation
The global radiopharmaceutical market is segmented based on type, type of test, application, route of administration, and end user.
By type, the market for radiopharmaceutical is segmented into diagnostic type radiopharmaceuticals and therapeutic type radiopharmaceuticals. The diagnostic type radiopharmaceutical segment is further sub-segmented into SPECT radiopharmaceutical and PET radiopharmaceutical. The therapeutic type radiopharmaceutical segment is further sub-segmented into beta emitters, alpha emitters, brachytherapy. The SPECT radiopharmaceutical segment is further sub-segmented into Technetium-99m, Thallium-201, Iodine-123, and others. The PET radiopharmaceutical segment is further sub-segmented into F-18, Rubidium-82, and others. The Beta emitters segment is further sub-segmented into Iodine-131, Yttrium-90, Samarium-153, Rhenium-186, Lutetium-177, and others. The brachytherapy segment is sub-segmented into Iodine-125, Iridium-192, Cesium-131, and others.
By application, the market is segmented into oncology, cardiology, neurology, urology, and others. The oncology segment is further segmented into prostate cancer, bone cancer, breast cancer and others. The cardiology segment is further segmented into coronary artery disease, cardiomyopathy and others. The neurology segment is further segmented into traumatic brain injury, stroke, Alzheimer’s disease and others. The urology segment is sub-segmented into acute pyelonephritis, congenital renal anomalies, and others.
By route of administration, the market is segmented into oral, intravenous and others.
By end user, the market is segmented into hospitals, diagnostic centers, research institutes and others.
Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/1650
Detailed Table of Contents:
TABLE OF CONTENTS
1 REPORT PROLOGUE
2 EXECUTIVE SUMMARY
3 MARKET INTRODUCTION
3.1 Scope Of Study 27
3.2 Research Objective 27
3.3 Assumptions & Limitations 27
3.3.1 Assumptions 27
3.3.2 Limitations 27
3.4 Market Structure 27
4 RESEARCH METHODOLOGY
4.1 Primary Research 29
4.2 Secondary Research 30
4.3 Market Size Estimation 31
4.4 Forecast Model 31
5 MARKET DYNAMICS
5.1 Introduction 33
5.2 Drivers 34
5.2.1 All-Rounder (Both Diagnostic & Treatment), Characteristics Of Radiopharmaceutical Driving The Market Growth (35%) 34
…Continued
Regional Analysis
The global radiopharmaceutical market is segmented into four regions namely the Americas, Europe, Asia Pacific, and the Middle East & Africa, with Americas holding the largest market share followed by Europe. The Americas dominate the global Radiopharmaceuticals market owing to the presence of huge patient population suffering from various chronic diseases like cancer, coronary disorders, stroke among others, changing lifestyle and increasing research & development for effective and therapies with no side effects. According to the National Cancer Institute, in 2016, 1.6 million new cases of cancer were diagnosed in the United States. Increasing investment in research & development and presence of the leading players in the market have fueled the market growth. Europe accounts for the second largest market for the radiopharmaceuticals, which is followed by Asia Pacific. Growing investment in research and presence of huge patient pool has driven the market in Europe. According to the European Cardiovascular Disease Statistics 2017 report, each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe. Asia Pacific is the fastest growing market owing to the huge population base, increasing the prevalence of chronic diseases, rapidly developing economies and increasing investments in healthcare. Moreover, growing awareness among individuals and rising diagnostic rates has fueled the demand for SPECT and PET devices in this region.
Players Covered
Some of the key players in this market are Jubilant Life Sciences Ltd., Siemens AG, Sun Pharmaceutical Industries Ltd., Bayer AG, Cardinal Health Inc., Medtronic, General Electric Company (GE Healthcare), Lantheus Medical Imaging, Inc., Advanced Accelerator Applications S.A., Mallinckrodt Pharmaceuticals, Nordion, Inc., Canadian Nuclear Laboratories (CNL), Bracco Diagnostic Inc., IBA Dosimetry GmbH, Avid Radiopharmaceuticals and few others.
The report offers insights on the prominent market players and gauges their current position in the market. Company information with regard to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives.
Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/1650
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
